Treatment of Lentigo Maligna with imiquimod 5% cream.

Not Applicable

Completed

• Conditions: Lentigo maligna; Skin - Other skin conditions; entigo maligna; Cancer - Malignant melanoma

• Registration Number: ACTRN12610000066088
• Lead Sponsor: Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-01-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

lentigo maligna greater than 5mm diiameter

Exclusion Criteria

detection of invasive melanoma

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clearance of lentigo maligna as demonstrated by histological assessment of the complete surgical excison specimen of the entire treated area post application of imiquimod[after the 12 weeks of imiquimod application an assessment is made and surgery is scheduled within the next 2 weeks depending on the expected time for the inflammation to settle as determined by the investigators]

Secondary Outcome Measures

Name	Time	Method
pathologist concordance in assessment of specimens[post surgical excision];relevance of inflammatory reaction to clearance of tumour as assessed by clinical review of the inflammatory reaction severity graded as none, mild , moderate or severe.[post surgical excision]